Clinical trial Recruiting at 1 site Interventional Ages 4 Months to 15

Children's nasal carriage of Streptococcus pneumoniae

Official title: Observatory of Streptococcus Pneumoniae Nasopharyngeal Carriage in Infants With Acute Otitis Media (AOM) and in Healthy Children"

Run by Association Clinique Thérapeutique Infantile du val de Marne · NCT04460313 · Data updated 2026-11-12

This project will test whether pneumococcal vaccines changed which Streptococcus pneumoniae types children carry in their noses and whether those bacteria became more resistant to antibiotics.

Quick facts

Study typeInterventional
Ages4 Months to 15 Years
SexAll
Enrollment29360 (estimated)
SponsorAssociation Clinique Thérapeutique Infantile du val de Marne
Academic / other
Locations1 site (Créteil)
StatusRecruiting
StartedSeptember 11, 2001
Main results expectedDecember 31, 2029
Study endsDecember 31, 2029
Registry record updatedOctober 27, 2026
Trial IDNCT04460313 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are children seen in participating outpatient pediatric clinics who are either 6–36 months with suppurative acute otitis media or healthy children aged 6 months–15 years, whose parents provide consent and who have not taken antibiotics within 7 days before enrollment.

Probably not a fit

Children with severe underlying disease, those enrolled in the study in the prior 12 months, those with bullous myringitis, or those recently treated with antibiotics are excluded and unlikely to benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Beginning in 2001, pediatricians in the ACTIV network across France enrolled children with suppurative acute otitis media (ages 6–36 months) and a separate group of healthy children (ages 6 months–15 years) during the October–June seasons each year. All participants had nasopharyngeal samples collected, with optional stool or anorectal swabs and an ancillary subgroup tested for ESBL-producing E. coli. Collected samples were serotyped and tested for antibiotic susceptibility to detect shifts in serotype distribution and resistance patterns after introduction of 7- and 13-valent pneumococcal conjugate vaccines. The study was conducted in outpatient pediatric settings with standardized sample collection and laboratory analysis over multiple years.

Why it matters

Potential benefit: If successful, the findings could help guide vaccine policy and antibiotic prescribing to reduce resistant pneumococcal infections in children.

How similar studies have gone: Other national and regional surveillance studies have documented vaccine-driven serotype shifts and changes in pneumococcal antibiotic resistance, so this approach is consistent with prior successful surveillance efforts.

Who can join: the full rules

Show full inclusion / exclusion criteria
children seen on an outpatient

Inclusion Criteria:

* both sexes
* suffering from suppurative AOM or healthy children

  * age: 4 months to 36 months for AOM
  * age: 4 months to 15 years for healthy children
* informed consent from parents or guardians
* Children who haven't received antibiotic treatment within 7 days before enrollment,

Exclusion Criteria:

* severe underlying disease,
* inclusion in the study during the previous 12 months
* Children with bullous myringitis cannot be included.

Where it's running

  • Activ
    Créteil, France
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.